Skip to main content
SpringerLink
Log in

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background

To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use programme, known as Temporary Authorization for Use (ATU). This programme was implemented to improve early access to drugs under development or authorized abroad. However, it is suspected to be inflationary, bypassing public bodies in charge of health technology assessment (HTA) and of pricing.

Objective

The aim of this study is to observe the market access after the formal licensing of drugs that went through this compassionate-use programme.

Methods

We included all ATUs that received an MA between 1 January 2005 and 30 June 2010. We first examined market access delays from these drugs using the standard administrative path. We positioned this result in relation to launch delays observed in France (for all outpatient drugs) and in other major European markets. Second, we assessed the bargaining power of a hospital purchaser after those drugs had obtained an MA by calculating the price growth rate after the approval.

Results

During the study period, 77 ATUs were formally licensed. The study concluded that, from the patient’s perspective, licensing and public bodies’ review time was shortened by a combined total of 36 months. The projected 11-month review time of public bodies may be longer than delays usually observed for outpatient drugs. Nonetheless, the study revealed significant benefits for French patient access based on comparable processing to launch time with those of other European countries with tight price control policies. In return, a 12 % premium, on average, is paid to pharmaceutical companies while drugs are under this status (sub-analysis on 56 drugs).

Conclusions

In many instances, the ATU programme responds to a public health need by accelerating the availability of new drugs even though this study suggests an impact of the programme on the market access of these drugs for which the standard administrative path is longer than usual. In addition, pharmaceutical companies seem to market compassionate-use drugs with a presumed benefit/risk ratio at a price that guarantees a margin for future negotiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Organisation for Economic Co-operation and Development. Pharmaceutical pricing policies in a global market: executive summary. Paris: OECD; 2008. http://www.oecd.org/dataoecd/36/2/41303903.pdf. Accessed 12 July 2011.

  2. Richter A. Assessing the impact of global price interdependencies. Pharmacoeconomics. 2008;26(8):649–59.

    Article  PubMed  Google Scholar 

  3. Danzon PM, Epstein AJ. Effects of regulation on drug launch and pricing in interdependent markets [NBER working paper no. 14041]. Cambridge: NBER; 2008.

  4. De Launet Q, Brouard A, Doreau C. Les autorisations temporaires d’utilisation (ATU): 50 ans d’histoire de l’évolution de la réglementation des médicaments en France. Revue d’Histoire de la Pharmacie. 2004;341:47–54.

    Article  Google Scholar 

  5. Article L.601-2 (new article L.5121-12) created by the 21st article of the law no 92-1279 of December 8th, 1992, French public health code [in French]. Journal Officiel de la République Française. 11 Dec 1992. no 288: 16888.

  6. Articles R5142-20 to R5142-30 created par the decree no 94-568 of July 8th, 1994, French public health code [in French]. Journal Officiel de la République Française. 10 Jul 1994. no 159: 9981.

  7. European Parliament and Council of the European Union. Article 83 of the Regulation EC/726/2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Strasbourg: European Parliament; 31 Mar 2004. Official Journal of the European Union. 30 Apr 2004. L 136/1-33.

  8. Agence Française de Sécurité Sanitaire des Produits de Santé. Notice to applicants for Temporary Authorisation for Use (ATU). Paris: AFSSAPS; 2007. http://ansm.sante.fr/Activites/Autorisations-Temporaires-d-Utilisation-ATU/ATU-Avis-aux-demandeurs-formulaires/(offset)/6. Accessed 3 Mar 2013.

  9. Cour des comptes. La sécurité sociale: rapport sur le projet de loi de financement de la sécurité sociale pour 2003. Paris: Cour des comptes; 2002. http://www.ccomptes.fr/fr/Publications/Publications/Securite-sociale-2002. Accessed 3 March 2013.

  10. Woronoff-Lemsi M-C, Grall J-Y, Monier B, et al. Le médicament à l’hôpital: rapport pour le Ministère de la Santé, de la Famille et des Personnes Handicapées. 2003. http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/034000374/0000.pdf. Accessed 3 Mar 2013.

  11. Amendment of the article L5121-12 of the French public health code by the article 56 of the law no 2006-1640 of December 21st, 2006, for the 2007 Financing Law of Social Security, [in French]. Journal Officiel de la République Française. 22 Dec 2006. no 296: 19315.

  12. Framework agreement of 25 September 2008 between the Comite Economique des Produits de Santé and the pharmaceutical companies (as amended by the riders of 26 October 2009 and 7 October 2010). Paris: CEPS; 2008. http://www.sante.gouv.fr/IMG/pdf/Accord_cadre_en_vigueur_version_anglaise_.pdf. Accessed 18 Aug 2011.

  13. NHI. Base des médicaments et informations tarifaires. http://www.codage.ext.cnamts.fr/codif/bdm_it/index_presentation.php. Accessed 3 Mar 2013.

  14. Ministère des Affaires Sociales et de la Santé. CEPS annual reports. http://www.sante.gouv.fr/les-activites-du-ceps.html. Accessed 3 Mar 2013.

  15. Ministerial Industry Strategy Group. Earlier access to medicines in the UK. London: MISG; 2009. http://www.mhra.gov.uk/home/groups/es-policy/documents/websiteresources/con065737.pdf. Accessed 5 Jan 2012.

  16. Rahbari M, Rahbari NN. Compassionate use of medical products in Europe: current status and perspectives. Bull World Health Organ. 2011;89:163.

    Google Scholar 

  17. Agence Française de Sécurité Sanitaire des Produits de Santé. Etat des lieux et propositions d’amélioration du dispositif de gestion des Autorisations Temporaires d’Utilisation (ATU): point d’information. Paris: AFSSAPS; 2011. http://ansm.sante.fr/var/ansm_site/storage/original/application/6dd66d1fdfcdabfa0786549c88437996.pdf. Accessed 3 Mar 2013.

  18. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs: evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14:269–92.

    Article  PubMed  Google Scholar 

  19. Juillard-Condat B, Rouch L, Durand M-C, et al. Achat des médicaments sous autorisation temporaire d’utilisation nominative. Gestions Hospitalières. 2010;499:515–21.

    Google Scholar 

  20. Gaillard L, Dey N, Meunier A, et al. Médicaments sous autorisation temporaire d’utilisation: limites du dispositif, expérience de la pharmacie centrale des hospices civils de Lyon (PC-HCL). Le Pharmacien Hospitalier. 2005;40(160):17–24.

    Google Scholar 

  21. Hermange MT. Rapport d’information No 675 fait au nom de la mission commune d’information, Mediator: évaluation et contrôle des medicaments [registered to the presidency of the Senate on 28 June 2011]. http://www.senat.fr/rap/r10-675-1/r10-675-11.pdf. Accessed 4 Mar 2013.

  22. French National Assembly. Document No 3881: projet de loi modifié par le Sénat relatif au renforcement de la sécurité sanitaire du médicament et des produits de santé [registered to the presidency of the National Assembly on 27 October 2011]. http://www.assemblee-nationale.fr/13/pdf/projets/pl3881.pdf. Accessed 4 Mar 2013.

  23. Law no 2011-2012 of December 29th, 2011, related to the strengthening of the safety of drugs and health products [in French]. Journal Officiel de la République Française. 30 Dec 2011. no 0302: 22667.

Download references

Acknowledgments

The authors gratefully acknowledge Dr Nicole Poisson and her team for their support in conducting this study, Raphaël Scalliet for his help in extracting data from the AGEPS databases, and Melissa Drewry for her helpful revisions. The authors also wish to thank IMS health for having provided the European data. The authors have no conflicts of interest that are directly relevant to the content of this article. Albane Degrassat-Théas, the corresponding author, acts as guarantor for the overall content.

Author information

Authors and Affiliations

  1. Laboratory of Economics and Management of Health Organizations (LEGOS), Paris-Dauphine University, Place du Maréchal de Lattre de Tassigny, 75016, Paris, France

    Albane Degrassat-Théas & Claude Le Pen

  2. Faculty of Pharmaceutical Sciences, Paris Descartes University, Sorbonne Paris Cité, Institut Droit et Santé, Paris, France

    Albane Degrassat-Théas & Pascal Paubel

  3. Pharmacy Department, General Agency of Equipment and Health Products (AGEPS), Public Welfare Hospitals of Paris (AP-HP), Paris, France

    Albane Degrassat-Théas, Olivier Parent de Curzon & Martine Sinègre

Authors
  1. Albane Degrassat-Théas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Paubel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Parent de Curzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claude Le Pen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martine Sinègre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albane Degrassat-Théas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Degrassat-Théas, A., Paubel, P., Parent de Curzon, O. et al. Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?. PharmacoEconomics 31, 335–343 (2013). https://doi.org/10.1007/s40273-013-0039-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-013-0039-4

Keywords

Search

Navigation